Evaluation of prevalence of 32 mutation in CCR5 gene in breast cancer patients in Rafsanjan city

(Received 24 August, 2008; Accepted 21 May, 2009)AbstractBackground and purpose: Chemokines and their receptors are expressed in different types of malignancies. CC chemokines MIP-1 (CCL3), MIP-1 (CCL4) and RANTES (CCL5) is believed to be anti-tumor and also aid to the metastasis in tumor microenvironment. CCR2 and CCR5 are special G-protein receptors for these chemokines. Due to the important role of CCR5 chemokine receptor in tumor biology, this project is designed to examine 32 mutation in CCR5 gene regards breast cancer.Materials and methods: This experimental study was performed during 2007-8 on 100 healthy adults and 36 breast cancer patients by Gap-PCR. The demographic information also was collected by questionner and t-test Chi-square was used for statistical analysis of data.Results: Our results showed that none of breast cancer patients had CCR5- 32 mutation while 3 (3%) cases of controls had heterozygotic form of this mutation.Conclusion: Our results showed that there is not any CCR5- 32 mutation in patients. Therefore, it appears that this mutation don’t play any role in breast cancer.J Mazand Univ Med Sci 2009; 19(70): 49-53 (Persian)